Inhibikase Therapeutics (IKT) Environmental, Social & Governance (ESG) Data

Employees

Data from SEC filings

Employee count

ESG framework mentions

In last year of SEC filings

Sustainability Accounting Standards Board (SASB)

No mentions

Global Reporting Initiative (GRI)

No mentions

Task Force on Climate-related Financial Disclosures (TCFD)

No mentions

UN Sustainable Development Goals (SDGs)

No mentions

ESG term mentions

In last year of SEC filings

Air Emission Environment Environmental Extreme Weather Forest Green Materials Nature Offset Oil Package Packaging Pandemic Raw Materials Toxic Waste Water Access African American Benefits Black Collective Bargaining Community Customer Death Demographic Disability Diversity Drug Pricing Employee Engagement Ethnicity Gender Health and Safety Health Care Healthcare Hire Hiring Hispanic Human Capital Injuries Injury Privacy Recall Recruit Recruitment Reimbursement Retention Retirement Safety Satisfaction Skilled Skills Social Societal Society Supplier Supply Chain Supply Chain Management Talent Training Union Volunteer Women Workers Anti-corruption Assessment Assurance Audit Bonus Bribery Chronic Classified Commitment Corporate Governance Department of Ethics Executive Compensation Expert Fraud Goals Governance Hedging Incentive Incentivize Independence Independent Innovation Investigation Lawsuit Leadership Litigation Long-term Majority Oversee Oversight Pledging Procurement Proxy Contest Purpose Quality Standard Recoup Reputation Reputational Research and Development Responsibility Responsible Special Meeting Strategy Sustainable Targets Tax Transparency Voting Rights

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM

The 2021 Annual Meeting of Stockholders (“Annual Meeting”) of Inhibikase Therapeutics, Inc. (the “Company”) was held on June 25, 2021. The following proposals were approved at the Annual Meeting by the votes indicated:
Proposal One: To elect one director to the board of directors of the Company to serve as the Class I director, to serve until the Company’s 2024 annual meeting of stockholders or until his respective successor is duly elected and qualified. The nominee for election was Milton H. Werner, Ph.D.
The following nominee was elected by the votes indicated to serve as the Class I director, to serve until the Company’s 2024 annual meeting of stockholders or until his respective successor is duly elected and qualified:

Name		Total Votes for Director				Total Votes Withheld from Director				Total Broker Non-Votes

Milton H. Werner, Ph.D.			6,172,090				25,573				720,818

Proposal Two: To ratify the appointment of CohnReznick LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021.


	Total Votes
For		6,892,719
Against		3,591
Abstain		22,171
Broker Non-Votes		0

-2-